Second, there are conflicting data on the effects of RAAS inhibition on ACE2 expression and how it relates to clinical outcomes in COVID-19, including the potential for ACE inhibitors and ARBs to ...

In a recent study posted to the medRxiv * preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

The new data, published this week in JAMA Network Open, show that after adjusting for multiple variables, COVID-19 patients treated with ACE inhibitors and ARBs had a significantly lower risk of death ...

Several diseases are treated with renin-angiotensin-aldosterone system (RAAS) inhibitors, such as angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and mineralocorticoid ...

Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode may worsen cardiorenal outcomes and increase the risk for death, investigators ...

Renin-angiotensin-aldosterone system (RAAS) inhibitors generally cause a reduction in proteinuria in patients with primary focal segmental glomerulosclerosis (FSGS), according to study findings ...

Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was associated with lower risk for aneurysm rupture compared with nonuse, according to ...

Use of renin-angiotensin-aldosterone system, or RAAS, antagonists such as ACE inhibitors or angiotensin receptor blockers was linked to reduced risk for colorectal cancer in the 3 years after an ...

“ACE inhibitors and ARBs exert opposite effects on angiotensin II” Angiotensinogen is produced mainly in the liver and fat cells, in response to poor perfusion, and acts as a pro-signal in the complex ...